| Theme |
Tumors and bone mineral metabolism |
| Title |
Bone-modifying agents for breast cancer patients receiving hormonal therapy |
| Author |
Atsushi Shimomura |
Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine |
| Author |
Shinzaburo Noguchi |
Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine |
| [ Summary ] |
Use of aromatase inhibitors for postmenopausal breast cancer patients induces a reduction of estrogen levels and a subsequent loss of bone mineral density, resulting in an increased rate of bone fracture. Bone-modifying agents, such as bisphosphonates and denosumab, have been shown to prevent the loss of bone mineral density in patients treated with aromatase inhibitors. |